CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 113 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q4 2020. The put-call ratio across all filers is 0.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $85,000 | +57.4% | 43,200 | 0.0% | 0.00% | – |
| Q4 2020 | $54,000 | -66.0% | 43,200 | -51.1% | 0.00% | – |
| Q3 2020 | $159,000 | -85.6% | 88,300 | -33.1% | 0.00% | -100.0% |
| Q2 2020 | $1,107,000 | +60.7% | 132,000 | +0.4% | 0.00% | – |
| Q1 2020 | $689,000 | +43.8% | 131,500 | +49.8% | 0.00% | – |
| Q4 2019 | $479,000 | +11.9% | 87,800 | 0.0% | 0.00% | – |
| Q3 2019 | $428,000 | -29.6% | 87,800 | 0.0% | 0.00% | – |
| Q2 2019 | $608,000 | -0.3% | 87,800 | 0.0% | 0.00% | – |
| Q1 2019 | $610,000 | +15.5% | 87,800 | -2.9% | 0.00% | – |
| Q4 2018 | $528,000 | +26.3% | 90,400 | +63.2% | 0.00% | – |
| Q3 2018 | $418,000 | +141.6% | 55,400 | +61.5% | 0.00% | – |
| Q2 2018 | $173,000 | +1.8% | 34,300 | +23.4% | 0.00% | – |
| Q1 2018 | $170,000 | +57.4% | 27,800 | +82.9% | 0.00% | – |
| Q4 2017 | $108,000 | +36.7% | 15,200 | +38.2% | 0.00% | – |
| Q3 2017 | $79,000 | +14.5% | 11,000 | 0.0% | 0.00% | – |
| Q2 2017 | $69,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $42,335,000 | 24.44% |
| MANGROVE PARTNERS IM, LLC | 552,200 | $4,633,000 | 1.13% |
| ETF MANAGERS GROUP, LLC | 3,707,912 | $31,109,000 | 1.10% |
| Ikarian Capital, LLC | 1,350,000 | $11,327,000 | 0.90% |
| GENERAL AMERICAN INVESTORS CO INC | 712,400 | $5,977,000 | 0.76% |
| AdvisorShares Investments LLC | 189,814 | $1,593,000 | 0.68% |
| Ikarian Capital, LLC | 1,000,000 | $8,390,000 | 0.67% |
| Granite Point Capital Management, L.P. | 1,123,600 | $9,427,000 | 0.48% |
| Carmignac Gestion | 3,773,440 | $31,659,000 | 0.44% |
| Omnia Family Wealth, LLC | 32,356 | $271,467,000 | 0.27% |